EN | RU
EN | RU

Help Support

Back

Gliadin-protected superoxide dismutase: A useful add-on to phototherapy to treat vitiligo

Gliadin-protected superoxide dismutase: A useful add-on to phototherapy to treat vitiligo Gliadin-protected superoxide dismutase: A useful add-on to phototherapy to treat vitiligo
Gliadin-protected superoxide dismutase: A useful add-on to phototherapy to treat vitiligo Gliadin-protected superoxide dismutase: A useful add-on to phototherapy to treat vitiligo

A prospective, 24-week, randomized, interventional, double-blind, monocentric, placebo-controlled study was conducted to determine the efficacy of GP-SOD associated with NB-UVB to treat non-segmental vitiligo.

See All

Key take away

In people suffering from vitiligo, the use of gliadin-protected superoxide dismutase (GP-SOD)  combined with narrowband ultraviolet B (NB-UVB) was found to be a valuable add-on with excellent tolerability and safety.

Background

A prospective, 24-week, randomized, interventional, double-blind, monocentric, placebo-controlled study was conducted to determine the efficacy of GP-SOD associated with NB-UVB to treat non-segmental vitiligo.

Method

The study incorporated 50 patients with vitiligo affecting >5% of the total body surface. Participants were given GP-SOD (1g per day for 12 weeks followed by 0.5g per day for 12 weeks, n=25) or placebo (n=25) in combo with twice-weekly sessions of phototherapy. The major outcome ascertained was total repigmentation rate at 24 weeks, in comparison with baseline, as evaluated by Vitiligo Extent Score (VES) on the standardized pictures.

Result

Following 24 weeks, a higher improvement in VES was witnessed in the GP-SOD arm when compared with the placebo arm, as illustrated in Table 1:


In both groups, there was good tolerance and no side effects.

Conclusion

The combination of GP-SOD and NB-UVB therapy is effective for managing vitiligo patients.

Source:

Journal of the European Academy of Dermatology and Venereology

Article:

Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: A 24-week prospective randomized placebo-controlled study

Authors:

E Fontas et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: